{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Oral+Switch",
    "query": {
      "intervention": "Oral Switch"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 240,
    "total_pages": 24,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Oral+Switch&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-03T04:49:17.989Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04538040",
      "title": "Bictegravir/Emtricitabine/Tenofovir Alafenide Plus Doravirine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "HIV-1-infection"
      ],
      "interventions": [
        {
          "name": "Bictegravir/emtricitabine/tenofovir alafenamide + Doravirine switch",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Quest Clinical Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "45 Years and older · Male only"
      },
      "enrollment_count": 20,
      "start_date": "2019-12-19",
      "completion_date": "2021-11-11",
      "has_results": true,
      "last_update_posted_date": "2024-03-05",
      "last_synced_at": "2026-09-03T04:49:17.989Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04538040"
    },
    {
      "nct_id": "NCT03285711",
      "title": "Study to Evaluate the Safety and Efficacy of Filgotinib and Lanraplenib in Adults With Lupus Membranous Nephropathy (LMN)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lupus Membranous Nephropathy"
      ],
      "interventions": [
        {
          "name": "Filgotinib",
          "type": "DRUG"
        },
        {
          "name": "Lanraplenib",
          "type": "DRUG"
        },
        {
          "name": "Filgotinib placebo",
          "type": "DRUG"
        },
        {
          "name": "Lanraplenib placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 9,
      "start_date": "2017-10-06",
      "completion_date": "2020-02-03",
      "has_results": true,
      "last_update_posted_date": "2020-05-18",
      "last_synced_at": "2026-09-03T04:49:17.989Z",
      "location_count": 7,
      "location_summary": "Birmingham, Alabama • Palo Alto, California • Gainesville, Florida + 4 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Lawrenceville",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03285711"
    },
    {
      "nct_id": "NCT03969901",
      "title": "Safety, Tolerability, Efficacy and Pharmacokinetics of Imipenem/Cilastatin/Relebactam (MK-7655A) in Pediatric Participants With Gram-negative Bacterial Infection (MK-7655A-021)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Suspected or Documented Gram-negative Bacterial Infection"
      ],
      "interventions": [
        {
          "name": "IMI/REL",
          "type": "DRUG"
        },
        {
          "name": "Active Control",
          "type": "DRUG"
        },
        {
          "name": "Oral Switch",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "Up to 17 Years"
      },
      "enrollment_count": 115,
      "start_date": "2019-10-08",
      "completion_date": "2024-05-07",
      "has_results": true,
      "last_update_posted_date": "2026-02-05",
      "last_synced_at": "2026-09-03T04:49:17.989Z",
      "location_count": 8,
      "location_summary": "Tucson, Arizona • Long Beach, California • San Diego, California + 5 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03969901"
    },
    {
      "nct_id": "NCT01050257",
      "title": "A Study of Intravenously Administered Tamiflu (Oseltamivir) in Patients Over 13 Years of Age With Influenza",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Oseltamivir IV",
          "type": "DRUG"
        },
        {
          "name": "Oseltamivir Oral",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "13 Years and older"
      },
      "enrollment_count": 118,
      "start_date": "2010-01",
      "completion_date": "2012-09",
      "has_results": true,
      "last_update_posted_date": "2013-11-01",
      "last_synced_at": "2026-09-03T04:49:17.989Z",
      "location_count": 56,
      "location_summary": "Birmingham, Alabama • Montgomery, Alabama • Phoenix, Arizona + 47 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01050257"
    },
    {
      "nct_id": "NCT06039579",
      "title": "Proof of Concept Treatment Study of Orally Administered VH4004280 or VH4011499 in HIV-1 Infected Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "VH4004280",
          "type": "DRUG"
        },
        {
          "name": "VH4011499",
          "type": "DRUG"
        },
        {
          "name": "VH4004280 Matching Placebo",
          "type": "DRUG"
        },
        {
          "name": "VH4011499 Matching Placebo",
          "type": "DRUG"
        },
        {
          "name": "Antiretroviral therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 44,
      "start_date": "2023-10-25",
      "completion_date": "2024-06-24",
      "has_results": true,
      "last_update_posted_date": "2025-09-30",
      "last_synced_at": "2026-09-03T04:49:17.989Z",
      "location_count": 3,
      "location_summary": "Bakersfield, California • DeLand, Florida • Newark, New Jersey",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "DeLand",
          "state": "Florida"
        },
        {
          "city": "Newark",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06039579"
    },
    {
      "nct_id": "NCT00065156",
      "title": "Lenalidomide Safety/Efficacy in Myelodysplastic Syndromes (MDS) Associated With a Deletion (Del)(5q) Cytogenetic Abnormality",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myelodysplastic Syndromes"
      ],
      "interventions": [
        {
          "name": "lenalidomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 148,
      "start_date": "2003-06-01",
      "completion_date": "2008-08-01",
      "has_results": true,
      "last_update_posted_date": "2019-11-19",
      "last_synced_at": "2026-09-03T04:49:17.989Z",
      "location_count": 31,
      "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Rancho Mirage, California + 22 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Rancho Mirage",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00065156"
    },
    {
      "nct_id": "NCT01077375",
      "title": "Study of Milnacipran in Patients With Inadequate Response to Duloxetine for the Treatment of Fibromyalgia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Fibromyalgia"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Milnacipran",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Forest Laboratories",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 107,
      "start_date": "2010-02",
      "completion_date": "2011-01",
      "has_results": true,
      "last_update_posted_date": "2012-01-26",
      "last_synced_at": "2026-09-03T04:49:17.989Z",
      "location_count": 26,
      "location_summary": "Sacramento, California • Cromwell, Connecticut • Danbury, Connecticut + 21 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Cromwell",
          "state": "Connecticut"
        },
        {
          "city": "Danbury",
          "state": "Connecticut"
        },
        {
          "city": "Delray Beach",
          "state": "Florida"
        },
        {
          "city": "Ocala",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01077375"
    },
    {
      "nct_id": "NCT00209027",
      "title": "The Effects of Aripiprazole on the Processing of Rewards in Schizophrenia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "fMRI",
          "type": "OTHER"
        },
        {
          "name": "Aripiprazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "50 Years",
        "sex": "MALE",
        "summary": "20 Years to 50 Years · Male only"
      },
      "enrollment_count": 20,
      "start_date": "2005-04",
      "completion_date": "2011-04",
      "has_results": true,
      "last_update_posted_date": "2013-12-06",
      "last_synced_at": "2026-09-03T04:49:17.989Z",
      "location_count": 1,
      "location_summary": "Decatur, Georgia",
      "locations": [
        {
          "city": "Decatur",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00209027"
    },
    {
      "nct_id": "NCT05869773",
      "title": "A Switch Study From High-Sodium Oxybate to Xywav to Evaluate Changes in Blood Pressure in Participants With Narcolepsy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Narcolepsy"
      ],
      "interventions": [
        {
          "name": "JZP258",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jazz Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 155,
      "start_date": "2023-06-26",
      "completion_date": "2025-03-10",
      "has_results": true,
      "last_update_posted_date": "2026-04-24",
      "last_synced_at": "2026-09-03T04:49:17.989Z",
      "location_count": 31,
      "location_summary": "Culver City, California • Encino, California • Huntington Beach, California + 27 more",
      "locations": [
        {
          "city": "Culver City",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Lakewood",
          "state": "California"
        },
        {
          "city": "Redwood City",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05869773"
    },
    {
      "nct_id": "NCT02732327",
      "title": "Comparative Study of Ceftazidime-Avibactam Versus Standard of Care as Therapy in Febrile Neutropenic Adults With Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neoplasms",
        "Febrile Neutropenia"
      ],
      "interventions": [
        {
          "name": "CAZ-AVI",
          "type": "DRUG"
        },
        {
          "name": "Vancomycin",
          "type": "DRUG"
        },
        {
          "name": "Linezolid",
          "type": "DRUG"
        },
        {
          "name": "Cefepime",
          "type": "DRUG"
        },
        {
          "name": "Meropenem",
          "type": "DRUG"
        },
        {
          "name": "Piperacillin/tazobactam",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Forest Laboratories",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2016-05-17",
      "completion_date": "2016-06-27",
      "has_results": true,
      "last_update_posted_date": "2017-07-21",
      "last_synced_at": "2026-09-03T04:49:17.989Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02732327"
    }
  ]
}